Retail investors buy Novo dip after disappointing weight-loss drug data
U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda Research.
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.
What went wrong with Novo Nordisk’s CagriSema obesity drug trial
The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares dropped to its lowest point since August 2023 after the disappointing trial r
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, below expectations for 25%.
Novo Nordisk Shares Drop 27% After Obesity Drug Trial Fails to Meet Expectations
Novo Nordisk A/S’s shares plummeted by 27% after its obesity treatment failed to meet expectations in a key trial. The drug helped patients lose weight, but the results fell short of the predicted target.
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
Novo Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal
Henrik Wulff, the man in charge of product supply at Novo Nordisk, just spent $11 billion to try to fill an ocean. Novo has ...
pharmaphorum2d
Novo Nordisk sheds billions in value on obesity data
Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...
Novo Nordisk shares plunge on the back of disappointing trial results
Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall ...
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
FiercePharma11d
Novo Nordisk’s chief scientific officer looks to the future of GLP-1s
GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...
Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...